MiMedx Group Inc
NASDAQ:MDXG
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.51
9.28
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
MiMedx Group Inc
MiMedx Group Inc
Research & Development
MiMedx Group Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MiMedx Group Inc
NASDAQ:MDXG
|
Research & Development
-$8.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.9B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-15%
|
|
MiMedx Group Inc
Glance View
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 811 full-time employees. The company went IPO on 2007-08-20. The firm is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD. The AMNIOFIX and EPIFIX are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. Its EPICORD and AMNIOCORD are tissue allografts derived from umbilical cord tissue. EPIFIX is a semi-permeable, protective barrier allograft comprised of dehydrated human amnion/chorion membrane that may be used in the treatment of chronic wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. AMNIOFIX is used in surgical recovery applications including in the areas of spine, orthopedic, sports medicine and urologic.
See Also
What is MiMedx Group Inc's Research & Development?
Research & Development
-8.8m
USD
Based on the financial report for Sep 30, 2024, MiMedx Group Inc's Research & Development amounts to -8.8m USD.
What is MiMedx Group Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-3%
Over the last year, the Research & Development growth was 63%. The average annual Research & Development growth rates for MiMedx Group Inc have been 18% over the past three years , 8% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
